Want to see PROK full AI Analyst Report?
PROK Stock Chart & Stats
$1.50
-$0.02(-1.32%)
At close: 4:00 PM EDT
$1.50
-$0.02(-1.32%)
Day’s Range― - ―
52-Week Range$1.45 - $3.55
Previous CloseN/A
Volume1.72M
Average Volume (3M)1.38M
Market Cap
$465.17M
Enterprise Value$1.32K
Total Cash (Recent Filing)$224.94M
Total Debt (Recent Filing)$3.78M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding205,199,700
10 Day Avg. Volume1,177,473
30 Day Avg. Volume1,376,340
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.75Price Target Upside283.33% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$511.14K
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment & Phase 3 ProgressFDA recognition of eGFR slope as a surrogate and a statistically powered Phase 3 on-track enrollment materially reduces regulatory uncertainty for rilparencel. That alignment supports an accelerated approval pathway and makes the pivotal trial's outcome a credible de-risking event for the program over the next 12–18 months.
Sufficient Near-term Cash RunwayA reported cash and securities balance (~$224.9M) backing operations into mid-2027 gives the company a durable runway through the pivotal topline readout. This materially lowers near-term refinancing pressure and enables consistent funding of clinical and CMC activities required to reach key regulatory milestones.
Low Financial LeverageVery low reported debt limits solvency risk and preserves strategic flexibility. With minimal interest burden, management can prioritize clinical execution and selective partnerships without immediate pressure from lenders, which is durable support for a development-stage biotech managing long R&D timelines.
Bears Say
High Cash BurnSustained, large negative operating and free cash flows indicate persistent funding need to support Phase 3 development and manufacturing scale-up. Over 2–6 months this structural burn rate means the company will likely need external capital or partnerships, creating dilution or negotiation pressure that affects long-term strategy.
Minimal, Declining Revenue BaseRevenue is negligible and declining, reflecting a lack of recurring commercial sales. As a clinical-stage firm, ProKidney remains fully dependent on R&D milestones, partnerships, or financings to create sustainable revenue streams, leaving commercialization and cash generation uncertain until approval and market adoption.
Large Operating Losses And Negative MarginsDeep and persistent operating losses driven by R&D and manufacturing spend produce structurally negative margins. This long-running unprofitability increases reliance on external funding, raises execution risk for commercialization plans, and limits flexibility to pursue parallel programs without partner support.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $1.45 and its highest was $3.55 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $465.17M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on May 15, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.002.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -0.14.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 205,199,700 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -2.924%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.75 (283.33% Upside)
$5.75 (283.33% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 54.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 4.1%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.90%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.75
▲(283.33% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
47.18% Insiders
1.99% Mutual Funds
0.95% Other Institutional Investors
47.37% Public Companies and
Individual Investors